Oncoinvent (ONCIN) Investor presentation summary

Unmet medical need and disease background

• Peritoneal metastases from various cancers have limited treatment options, with surgery as the only curative approach and high relapse rates due to residual micrometastases.

• Ovarian cancer patients frequently present with peritoneal micrometastases, and up to 85% relapse after resection, with recurrence mainly in the peritoneum.

• Controlling residual or reseeded disease post-surgery is crucial for improving survival and quality of life.

Product overview and mechanism

• RadspherinⓇ is an alpha-emitting radiopharmaceutical (224Ra on CaCO3 microparticles) designed for local retention in the peritoneum.

• Administered 1-3 days post-surgery, it delivers a high dose of radiation to micrometastases while sparing normal tissue.

• Single-dose administration fits into existing clinical workflows and minimizes patient burden.

• The mechanism is independent of tumor origin or mutation, enabling broad applicability across peritoneal-spreading cancers.

Clinical efficacy and safety

• In ovarian cancer Phase 1, 90% of patients remained free of peritoneal recurrence at 24 months, with overall recurrence at 30%.

• In colorectal cancer Phase 1/2a, 72% remained recurrence-free at 18 months, with a peritoneal recurrence rate of 28% versus 50% in literature benchmarks.

• No dose-limiting toxicity observed across 68 patients; adverse events were expected and manageable.

• Only three serious adverse events possibly related to RadspherinⓇ were reported.